Australia's most trusted
source of pharma news
Posted 29 November 2021 PM
The race is on to develop a vaccine against the latest variant of COVID-19, Omicron, with the main vaccine developers offering reassurance that they are already on the case - and a new jab could be ready in early 2022.
The new variant of concern has been dubbed Omicron by the World Health Organisation, continuing its tradition of using Greek letters to make it simpler to communicate than using the scientific name, and avoiding offence by referring to the virus by the place it was first identified.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.